Pediatric Allergy and Immunology: Ledger

Stories naming Pediatric Allergy and Immunology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
Pediatric Allergy and Immunology is not recorded as having acquired anything.

Name	Role	Sources
Dr Robert A. Wood	Deputy Editor (former)	Brandon Capital portfolio

Key hire

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

Aravax clears its US FDA application to trial its peanut-allergy immunotherapy PVX108 in Phase 2 studies across two countries, and adds a prominent food-allergy paediatric specialist to its scientific advisory board.

Brandon Capital portfolio 4 Mar 2022 Annals of Allergy, Asthma, and Immunology Aravax Johns Hopkins Bloomberg School of Public Health Johns Hopkins Children's Center Johns Hopkins University School of Medicine Journal of Allergy and Clinical Immunology Pediatric Allergy and Immunology The Johns Hopkins Hospital Dr Pascal Hickey Dr Robert A. Wood

Pediatric Allergy and Immunology

Funding history

Investors

What Pediatric Allergy and Immunology bought

People

Coverage

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy